Winnipeg, MN – January 27, 2004 – Dr Geoffrey Grant has been named to the board of Kane Biotech. He is currently the director of the Arlington Technology Incubator (ATI) at the University of Texas. Previous to joining the ATI, he spent five years as the senior manager of research and technology at the University of North Texas Health Science Center at Fort Worth, where he led and managed all aspects of technology commercialization and intellectual property protection.
From 1991 until 1993, Dr Grant served with Micrologix Biotech (formerly Microtek). During his time as CEO for Micrologix, he oversaw the transition from a privately held entity to a publicly traded company. Following his experience at Micrologix, Dr Grant served as an independent biotech industry consultant in California until joining the University of North Texas Health Science Center at Fort Worth in 1998.
Dr. Grant received his BSc and MSc from the University of British Columbia and PhD in genetics and cell biology from the University of California – San Diego. He began his career as a researcher, serving at the Salk Institute of Biological Studies in San Diego as a part of the neuroendocrinology group. In addition to authoring numerous publications, grants and patents, he was the co-discoverer of Somatostatin, which became the first genetically engineered peptide made commercially available. Somatostatin was commercialized by Genentech.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms.